



JFW

Attorney Docket No.: 6659.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ezban et al.

Application No.: 10/822,943

Group Art Unit: To be assigned

Filed: April 12, 2004

Examiner: To be assigned

For: Use of TF Antagonists

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed. The references are as follows:

1. WO 92/15686
2. WO 94/27631
3. WO 96/12800
4. WO 97/47651
5. WO 90/03390
6. WO 95/00541


7. WO 96/18653
8. WO 01/21661
9. WO 01/02439
10. WO 98/03632
11. EP 500800
12. Hu, Zhiwei et al., Proc Natl Acad. Sci., Vol. 98 (21), pp. 12180-85 (2001)
13. Hu, Zhiwei et al., Proc Natl Acad Sci., Vol. 97 (16), pp. 9221-9225 (2000)
14. Hu, Zhiwei et al., Proc Natl Acad Sci., Vol. 96, pp. 8161-66 (1999)
15. Burgess, Laurence E. et al., Proc Natl Acad Sci., Vol. 996, pp. 8348-52 (1999)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: August 18, 2004

Respectfully submitted,



Len S. Smith, Reg. No. 43,139
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE



Attorney Docket No.: 6659.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ezban et al.

Serial No.: 10/822,943

Group Art Unit: To be assigned

Filed: April 12, 2004

Examiner: To be assigned

For: Use of TF Antagonists

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on **August 18, 2004**

Csaba Attila Szakolczai
(name of person mailing paper)

Csaba Attila Szakolczai
(signature of person mailing paper)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6659.200-US

Serial No. 10/822,943

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTApplicant **Ezban et al.**

(Use several sheets if necessary)

Filing Date **April 12, 2004**Group **To be assigned**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 92/15686	09/17/1992	PCT				
	WO 94/27631	12/08/1994	PCT				
	WO 96/12800	05/02/1996	PCT				
	WO 97/47651	12/18/1997	PCT				
	WO 90/03390	04/05/1990	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Hu, Zhiwei et al., Proc Natl Acad. Sci., Vol. 98 (21), pp. 12180-85 (2001)
		Hu, Zhiwei et al., Proc Natl Acad. Sci., Vol. 97 (16), pp. 9221-9225 (2000)
		Hu, Zhiwei et al., Proc Natl Acad. Sci., Vol. 96, pp. 8161-66 (1999)
		Burgess, Laurence E. et al., Proc Natl Acad. Sci., Vol. 996, pp. 8348-52 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6659.200-US

Serial No. 10/822,943

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant **Ezban et al.**Filing Date **April 12, 2004**Group **To be assigned**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 95/00541	01/05/1995	PCT				
		WO 96/18653	06/20/1996	PCT				
		WO 01/21661 A1	03/29/2001	PCT				
		WO 01/02439	01/11/2001	PCT				
		WO 98/03632	01/29/1998	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

